MyMD Pharmaceuticals Alpha and Beta Analysis
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as MyMD Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in MyMD Pharmaceuticals over a specified time horizon. Remember, high MyMD Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to MyMD Pharmaceuticals' market risk premium analysis include:
Beta (0.64) | Alpha (0.72) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
MyMD |
MyMD Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. MyMD Pharmaceuticals market risk premium is the additional return an investor will receive from holding MyMD Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in MyMD Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate MyMD Pharmaceuticals' performance over market.| α | -0.72 | β | -0.64 |
MyMD Pharmaceuticals Fundamentals Vs Peers
Comparing MyMD Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze MyMD Pharmaceuticals' direct or indirect competition across all of the common fundamentals between MyMD Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as MyMD Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of MyMD Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare MyMD Pharmaceuticals to competition |
| Fundamentals | MyMD Pharmaceuticals | Peer Average |
| Return On Equity | -1.01 | -0.31 |
| Return On Asset | -0.5 | -0.14 |
| Current Valuation | 2.99 M | 16.62 B |
| Shares Outstanding | 2.37 M | 571.82 M |
| Shares Owned By Insiders | 6.61 % | 10.09 % |
| Shares Owned By Institutions | 6.62 % | 39.21 % |
| Number Of Shares Shorted | 263.62 K | 4.71 M |
MyMD Pharmaceuticals Opportunities
MyMD Pharmaceuticals Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | PharmaCyte Biotech Makes 7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease | 05/21/2024 |
2 | Disposition of 3854626 shares by Pharmacyte Biotech, Inc. of MyMD Pharmaceuticals at 1.816 subject to Rule 16b-3 | 05/23/2024 |
3 | MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer | 06/17/2024 |
4 | MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. | 07/22/2024 |
5 | TNF Pharmaceuticals Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today - StockTitan | 07/24/2024 |
About MyMD Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including MyMD or other delisted stocks. Alpha measures the amount that position in MyMD Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
MyMD Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of MyMD Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MyMD Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of MyMD Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of MyMD Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of MyMD Pharmaceuticals' management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with MyMD Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |